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Update on Avian Influenza A (H5N1)
This update reviews the current situation and the surveillance and diagnostic recommendations for avian 
influenza A (H5N1). The recommendations for avian influenza A (H5N1) remain at the enhanced level established 
in February 2004. As detailed in the recommendations below, vigilance in the clinical setting for avian influenza 
(H5N1) requires that health-care providers consistently obtain international travel and other exposure risk 
information for persons who have specified respiratory symptoms.
Current Situation
On August 12, 2004, the Vietnamese Ministry of Health officially reported to the World Health Organization (WHO; 
see http://www.who.int/csr/don/2004_08_12/en/) three human deaths from confirmed avian influenza H5 infection. 
Additional tests are needed to determine whether the virus belongs to the same H5N1 strain that caused 22 
cases (15 deaths) in Vietnam and 12 cases (8 deaths) in Thailand earlier this year.
Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand, and Vietnam were previously affected by 
widespread H5N1 outbreaks in poultry during early 2004. At that time, more than 100 million birds either died from 
the disease or were culled (killed) in efforts to contain the outbreaks. Human cases (34 in all) were reported only 
in Thailand and Vietnam. The last case officially confirmed and reported to the WHO by Vietnam occurred in 
February 2004.
Beginning in late June 2004, however, new lethal outbreaks of highly pathogenic avian influenza A (H5N1) among 
poultry were reported to the World Organization for Animal Health (OIE) by China, Indonesia, Thailand, and 
Vietnam. The deaths reported by Vietnam on August 12 are the first reported human cases associated with this 
second wave of H5N1 infection among poultry. CDC is in communication with WHO and will continue to monitor 
the situation.
Enhanced U.S. Surveillance, Diagnostic Evaluation, and Infection Control Precautions for Avian Influenza A 
(H5N1)
CDC recommends maintaining the enhanced surveillance efforts by state and local health departments, hospitals, 
and clinicians to identify patients at increased risk for avian influenza A (H5N1) that were issued by CDC on 
February 3, 2004 (see http://www.cdc.gov/flu/han020302.htm). Guidelines for enhanced surveillance are:
Testing for avian influenza A (H5N1) is indicated for hospitalized patients with:
a. Radiographically confirmed pneumonia, acute respiratory distress syndrome (ARDS), or other severe 
respiratory illness for which an alternate diagnosis has not been established, AND
b. History of travel within 10 days of symptom onset to a country with documented H5N1 avian influenza 
in poultry and/or humans (for a regularly updated listing of H5N1-affected countries, see the OIE Web 
site at http://www.oie.int/eng/en_index.htm and the WHO Web site at http://www.who.int/en/).
Testing for avian influenza A (H5N1) should be considered on a case-by-case basis in consultation with state and
local health departments for hospitalized or ambulatory patients with:
a. Documented temperature of >38°C (>100.4°F), AND
b. One or more of the following: cough, sore throat, shortness of breath, AND
b. History of contact with poultry (e.g., visited a poultry farm, a household raising poultry, or a bird market)
or a known or suspected human case of influenza A (H5N1) in an H5N1-affected country within 10 
days of symptom onset.
Infection control precautions for H5N1 remain unchanged from the CDC interim recommendations published on 
February 3, 2004 http://www.cdc.gov/flu/han020302.htm. These recommendations are further described in the 
CDC guidance document, “ Interim Recommendations for Infection Control in Health-Care Facilities Caring for 
Patients with Known or Suspected Avian Influenza” http://www.cdc.gov/flu/avian/professional/infect-control.htm.
Laboratory Testing Procedures
Highly pathogenic avian influenza A (H5N1) is classified as a select agent and must be worked with under 
Biosafety Level (BSL) 3+ laboratory conditions. This includes controlled access double door entry with change 
room and shower, use of respirators, decontamination of all wastes, and showering out of all personnel. 
Laboratories working on these viruses must be certified by the U.S. Department of Agriculture. CDC does not 
recommend that virus isolation studies on respiratory specimens from patients who meet the above criteria be 
conducted unless stringent BSL 3+ conditions can be met. Therefore, respiratory virus cultures should not be 
performed in most clinical laboratories and such cultures should not be ordered for patients suspected of having 
H5N1 infection.
Clinical specimens from suspect A (H5N1) cases may be tested by PCR assays using standard BSL 2 work 
practices in a Class II biological safety cabinet. In addition, commercial antigen detection testing can be 
conducted under BSL 2 levels to test for influenza.
Specimens from persons meeting the above clinical and epidemiologic criteria should be sent to CDC if
• The specimen tests positive for influenza A by PCR or by antigen detection testing, OR
• PCR assays for influenza are not available at the state public health laboratory.
Because the sensitivity of commercially available rapid diagnostic tests for influenza may not always be optimal, 
CDC also will accept specimens from persons meeting the above clinical criteria even if they test negative by 
influenza rapid diagnostic testing if PCR assays are not available at the state laboratory.
Requests for testing should come through the state and local health departments, which should contact (404) 
639-3747 or (404) 639-3591 and ask for the epidemiologist on call before sending specimens for influenza A 
(H5N1) testing.
Additional Avian Influenza A (H5N1) Information
• For information about reported outbreaks of avian influenza A (H5N1) among poultry, see the web site of the
World Organization of Animal Health (OIE) at http://www.oie.int/eng/AVIAN_INFLUENZA/home.htm.
• For information about human H5N1 cases, see the WHO web site http://www.who.int/en/
• For clinical information about human H5N1 cases, see:
o CDC. Cases of influenza A (H5N1) - Thailand, 2004. MMWR 2004;53:100-103 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5305a2.htm.
o Hien TT, Liem AT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. New England 
Journal of Medicine 2004;350:1179-1188.
• For general information about influenza, see the CDC website at www.cdc.gov/flu.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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